Antibody

Abstract

Provided is an antibody effective in the treatment of tumors and the like. An antibody that includes an N-type glycosylation site of human CD98hc and recognizes an epitope exposed by inhibition of N-type glycosylation modification.

1 . (canceled) 
     
     
         2 . An anti-CD98hc antibody, whose affinity for a CD98hc variant in which amino acid residues at positions 395 to 397 or positions 400 and 401 of human CD98hc are replaced by amino acid residues of mouse-originated CD98hc is equivalent to its affinity for the mouse-originated CD98hc. 
     
     
         3 . (canceled) 
     
     
         4 . The antibody according to  claim 2 , comprising
 a heavy chain variable region comprising
 a heavy chain CDR1 comprising an amino acid sequence containing the amino acid sequence of SEQ ID NO: 1, 
 a heavy chain CDR2 comprising an amino acid sequence containing the amino acid sequence of SEQ ID NO: 2, and/or 
 a heavy chain CDR3 comprising an amino acid sequence containing the amino acid sequence of SEQ ID NO: 3; and/or 
   a light chain variable region comprising
 a light chain CDR1 comprising an amino acid sequence containing the amino acid sequence of SEQ ID NO: 6, 
 a light chain CDR2 comprising an amino acid sequence containing the amino acid sequence of SEQ ID NO: 7, and/or 
 a light chain CDR3 comprising an amino acid sequence containing the amino acid sequence of SEQ ID NO: 8. 
   
     
     
         5 . The antibody according to  claim 2 , comprising
 a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4, and/or   a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9.   
     
     
         6 . The antibody according to  claim 2 , which is Fv, scFv, diabody, triabody, tetrabody, or a combination thereof. 
     
     
         7 . The antibody according to  claim 2 , which is a monoclonal antibody. 
     
     
         8 . The antibody according to  claim 2 , which is a chimeric antibody, a humanized antibody, or a human antibody. 
     
     
         9 . The antibody according to  claim 2 , which is an immunoglobulin, Fab, F(ab)′, minibody, scFv-Fc, or a combination thereof. 
     
     
         10 . The antibody according to  claim 2 , having a substance having cytotoxic activity, an enzyme, a tag, or an immunomodulator bound thereto. 
     
     
         11 . A polynucleotide encoding the antibody according to  claim 2 . 
     
     
         12 . A chimeric antigen receptor, whose epitope is identical to an epitope for the antibody according to  claim 2 . 
     
     
         13 . A pharmaceutical composition comprising the antibody according to  claim 2 . 
     
     
         14 . A pharmaceutical composition comprising the chimeric antigen receptor according to  claim 12 .